Sanofi’s Stock Soars Amid Dupixent Breakthrough and Strong Technical Signals

Sanofi NV SNY is garnering investor attention as it showcases its strengths in biotechnology. The stock recently entered bullish territory, exhibiting a Golden Cross—a technical indicator often associated with potential price gains.

With momentum traders entering the fray and a significant breakthrough from Sanofi’s Dupixent, the stock is taking center stage in the market.

Strong Bullish Signals for Sanofi’s Stock

Chart created using Benzinga Pro

Year-to-date, Sanofi’s stock has climbed 21.89%. Its moving averages—eight-day, 20-day, 50-day, and even 200-day—are all trending upward.

Additionally, the stock has achieved a Golden Cross, where the 50-day moving average crosses above the 200-day moving average, signaling a potential long-term uptrend.

Currently, the MACD (moving average convergence/divergence) stands at 1.77, indicating bullish tendencies. The RSI (relative strength index) is at 69.91, nearing overbought territory, suggesting that the uptrend may still have further to go.

Read also: Top 3 Health Care Stocks That May Keep You Up At Night In Q1

A Major Breakthrough from Dupixent

Sanofi’s blockbuster drug Dupixent is in the spotlight after delivering promising Phase 2/3 trial results for the treatment of bullous pemphigoid (BP).

The results show that Dupixent enhances disease remission while significantly reducing severity. Crucially, it also minimizes the reliance on corticosteroids—possibly paving the way for a pioneering treatment in this area.

With regulatory submissions currently under review in the US and EU, the FDA has granted priority review status, expecting a decision by June 2025.

If approved, Dupixent could access yet another lucrative market, bolstering its already impressive reputation as a blockbuster treatment.

As Sanofi maintains its upward momentum with a Golden Cross and anticipation surrounding an important FDA decision, investors are keeping a close eye and anticipating potential future gains.

Read Next:

Image: Shutterstock